News
CRISPR Therapeutics benefits from Casgevy’s approval and a deep pipeline, despite early rollout hurdles and cost challenges.
Hosted on MSN1mon
Sickle cell trait vs. Sickle cell disease: Key differencesWhile both sickle cell trait and sickle cell disease involve mutations in the haemoglobin gene, they are fundamentally different in terms of symptoms, severity, and impact on daily life.
Some lucky people have rare genetic mutations that enable them to feel well-rested after just four hours of sleep, while the rest of us need around eight hours to function. Now, researchers have ...
Despite reports of a sickle cell patient being cured by gene therapy, columnist Oluwatosin Adesoye explains why she remains skeptical.
One-third of all indigenous inhabitants of Sub-Saharan Africa carry the gene ... of a specific form of sickle-cell disease in which there is homozygosity for the mutation that causes HbS.
Modern HIV medicine is based on a common genetic mutation. Now, researchers have traced where and when the mutation arose -- and how it protected our ancestors from ancient diseases.
More perceived social support from classmates was tied to less disease severity in children with sickle cell anemia in ...
CRISPR Therapeutics, whose CEO is Samarth Kulkarni, and Vertex Pharmaceuticals earned the first U.S. Food and Drug ...
Patients with sickle cell disease (SCD) continue to face severe complications, despite advances in treatment that have helped mitigate some risks. Increased ...
First Patient Dosed in the Phase 1/2 Study of BEAM-301 in Glycogen Storage Disease Type Ia, Beam’s Second Clinical Stage In ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results